Expression and clinical significance of PLEKHA5 in small cell lung cancer tissues

HUANG Yanhua; SHI Yujia; YIN Xiaowei.

doi:10.3969/j.issn.1009-0460.2019.07.005

Abstract：Objective To investigate the expression of PLEKHA5 in small cell lung cancer (SCLC) and its relationship with clinicopathological characteristics and prognosis. Methods From January 2012 to December 2017, cancer tissues and adjacent tissues of 85 patients with SCLC were collected. Quantitative real?time PCR ( QPCR) and immunohistochemistry were used to detect the ex?pression of PLEKHA5 in the above tissues.Patients received intravenous chemotherapy with etoposide／cisplatin (EP) regimen.The re?lationship between the expression of PLEKHA5 and clinicopathologic characteristics, overall survival ( OS) and brain metastasis?free survival (BMFS) was analyzed.Results The relative expression of PLEKHA5 mRNA in SCLC tissues was 1. 363±0. 469, higher than 1. 016±0. 241 in adjacent tissues ( P＜0. 05). Immunohistochemistry showed that PLEKHA5 score in SCLC tissues was 3. 86±1. 84, higher than 0. 89 ±0. 51 in adjacent tissues (P＜ 0. 05).The expression level of PLEKHA5 was not associated with gender, age, smok?ing history, tumor size, TNM stage and disease stage(P＞ 0. 05), but related to distant metastasis (brain metastasis) with statistic sig?nificance(P＝0. 017). Kaplan?Meier analysis showed that the median BMFS of PLEKHA5 high?expression group was 17. 8 months, lower than 24. 0 months of low?expression group (P＜0. 05).The median OS of PLEKHA5 high?expression group was 22. 8 months, and that of low expression group was not yet reached (＞60. 0 months), and the median OS of high?expression group was lower than that of low?expression group (P＜0. 05). Conclusion The expression of PLEKHA5 is up?regualted in SCLC tissues. The high expression of PLEKHA5 is associated with brain metastasis, short OS and BMFS. PLEKHA5 is an adverse prognostic factor of SCLC.